Peregrine Pharma (PPHM) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Roth Afirms Peregrine Pharma (PPHM) at Buy Following Q2 Numbers; Looking to Data-Heavy 2015
December 11, 2014 9:58 AM ESTRoth Capital maintains Peregrine Pharmaceuticals (Nasdaq: PPHM) at Buy with a price target of $5 following Q2 data released after markets closed Wednesday.
Analyst Joseph Pantginis noted that Peregrine reported Q2 loss of $0.07 per share, versus his estimate of an $0.08 per share loss. The... More
